Previous Article | Next Article 
Journal of Virology, September 2000, p. 8188-8193, Vol. 74, No. 17
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Characterization of a Replication-Defective Human
Immunodeficiency Virus Type 1 att Site Mutant That Is
Blocked after the 3' Processing Step of Retroviral
Integration
Hongmin
Chen and
Alan
Engelman*
Department of Cancer Immunology and AIDS,
Dana-Farber Cancer Institute, and Department of Pathology, Harvard
Medical School, Boston, Massachusetts 02115
Received 27 January 2000/Accepted 7 June 2000
 |
ABSTRACT |
Two activities of retroviral integrase, 3' processing and DNA
strand transfer, are required to integrate viral cDNA into a host cell
chromosome. Integrase activity has been analyzed in vitro using
purified protein and recombinant DNA substrates that model the U3 and
U5 ends of viral cDNA or by using viral preintegration complexes (PICs)
that form during virus infection. Numerous studies have investigated
changes in integrase or viral DNA for effects on both 3' processing and
DNA strand transfer activities using purified protein, but similar
analyses have not been carried out using PICs. Here, we analyzed PICs
from human immunodeficiency virus type 1 (HIV-1) strain 604del, an
integration-defective mutant lacking 26 bp of U5, and revE1, a
revertant of 604del containing an additional 19-bp deletion, for levels
of 3' processing activity that occurred in infected cells and for
levels of in vitro DNA strand transfer activity. Whereas revE1
supported one-third to one-half of the level of wild-type DNA strand
transfer activity, the level of 604del DNA strand transfer activity was
undetectable. Surprisingly, integrase similarly processed the 3' ends
of 604del and revE1 in vivo. We therefore conclude that 604del is
blocked in its ability to replicate in cells after the 3' processing
step of retroviral integration. Whereas Western blotting showed that wild-type, revE1, and 604del PICs contained similar levels of integrase
protein, Mu-mediated PCR footprinting revealed only minimal protein-DNA
complex formation at the ends of 604del cDNA. We propose that 604del is
replication defective because proteins important for DNA strand
transfer activity do not stably associate with this cDNA after in vivo
3' processing by integrase.
 |
TEXT |
Retroviral DNA integration requires
a series of DNA cutting and joining reactions catalyzed by the viral
integrase protein. Integrase recognizes and acts on the viral DNA
attachment (att) site, which is comprised of U3 and U5
sequences at the ends of viral cDNA. In an initial 3' processing
reaction, integrase cleaves each DNA end adjacent to the conserved
sequence CA. In the case of human immunodeficiency virus type 1 (HIV-1), 2 nucleotides are removed from each end, yielding 3'-hydroxyl
groups. In the subsequent DNA strand transfer step, integrase uses
these 3'-OHs to make a double-stranded staggered cut in chromosomal
DNA, which at the same time joins the viral 3' ends to 5'-phosphates at
the site of integration. The mechanism of the final step of retroviral integration, gap repair, remains to be elucidated and may require either viral proteins, cellular machinery, or both (see reference 2 for a detailed review of retroviral integration).
Retroviral integrase activity can be analyzed in vitro using purified
protein and recombinant DNA substrates that model the U3 and U5 ends of
viral cDNA (6, 9, 18, 20, 22, 33, 37, 38). Alternatively,
strand transfer of endogenous cDNA can be analyzed using
integrase-containing preintegration complexes (PICs) following their
isolation from infected cells (3-5, 7, 8, 12, 16, 17, 25, 27,
39). Levels of 3' processing activity promoted by integrase as an
in vivo PIC component can be quantified by digesting isolated
deproteinized cDNA with restriction enzymes and probing each 3' end for
loss of 2 nucleotides (4, 17, 25, 27-29, 31). Whereas
numerous integrase, U3, and U5 mutations have been analyzed for their
effects on the 3' processing and DNA strand transfer activities of
purified integrase proteins (6, 9-11, 15, 19-24, 32,
34-37), such mutations have not been analyzed for effects on
both 3' processing and DNA strand transfer as catalyzed by the PICs
that mediate viral integration in vivo. By doing so, we identify in
this report an HIV-1 att site mutant that is blocked in its
ability to replicate in cells after the 3' processing step of
retroviral integration.
HIV-1 strain 604del is a replication-defective deletion mutant lacking
26 bp of U5 upstream of the conserved CA dinucleotide. During tissue
culture passage, a revertant of 604del, designated revE1, that lacks an
additional 19 bp extending upstream from the original change was
isolated (35). Cells infected with wild type, 604del, and
revE1 contained similar levels of unintegrated HIV-1 DNA
(35). Since wild-type, 604del, and revE1 virions were released similarly from cells following transfection and contained similar levels of viral RNA, oligonucleotide substrates that model the
different U5 ends of these viruses were used to assess the in vitro 3'
processing and DNA strand transfer activities of purified HIV-1
integrase protein (35). Whereas 604del substrates supported about 10 and 4% of wild-type 3' processing and DNA strand transfer, respectively, revE1 was about 25 and 22% active, respectively. Thus,
these results were consistent with the notion that 604del was
integration defective in infected cells and that the novel U5 end
present in revE1 repaired this replication defect (35). There are instances, however, where results of in vitro integration assays do not reflect what occurs in vivo. For example, in vitro 3'
processing and DNA strand transfer activities of purified HIV-1 integrase were undetectable using a U3 oligonucleotide substrate with
changes at the conserved CA dinucleotide (23), and yet these
changes reduced the integration of a U3 mutant virus only 2.5-fold in
infected cells (26). Also, simian immunodeficiency virus
(SIV) integrase containing the substitution of Lys for Glu-136 (E136K)
restored an in vivo replication defect to SIV att site mutant strain 7, but purified SIV E136K integrase did not show any
preference over wild-type integrase for synthetic mutant 7 substrates
in vitro (11). With these results in mind, we further characterized the in vivo replication block of HIV-1 mutant 604del by
analyzing PICs derived from infected cells.
Wild-type, 604del, and revE1 virus stocks were produced by transfecting
293T cells, and C8166 T cells were infected with these stocks, as
previously described (8). Eight hours postinfection, cells
were lysed and cytoplasmic extract was prepared as previously described
(8). This cell extract, which contains HIV-1 PICs in their
native form, was analyzed using a variety of techniques to determine
levels of integrase catalytic activities and associated protein content
(Fig. 1). Specifically, the crude
cytoplasmic extract was examined by indirect end labeling to detect the
structures of U3 and U5 ends and quantitate in vivo 3' processing
activity and in in vitro integration assays to detect levels of
unintegrated HIV-1 cDNA and quantify DNA strand transfer activity. To
examine the extent of protein-DNA complex formation at the ends of
HIV-1 cDNA, PICs first purified by Nycodenz gradient centrifugation were analyzed by Mu-mediated PCR (MM-PCR) footprinting as previously described (8). Purified PICs were also analyzed by Western blotting to determine levels of integrase protein (Fig. 1).

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 1.
Experimental strategy to assess integrase catalytic
activities and PIC protein content. Cytoplasmic extract of
HIV-1-infected cells was processed in the indicated ways to determine
levels of integrase 3' processing activity that occurred in infected
cells, levels of in vitro DNA strand transfer activity, and levels of
PIC-associated proteins as detected by MM-PCR footprinting and Western
blotting. IN, integrase.
|
|
To measure the level of PIC-associated DNA strand transfer activity,
cytoplasmic extract (0.25 ml) was reacted with
X174 target DNA as
described previously (8). Integration reactions were
terminated and analyzed by Southern blotting also as previously described (8). DNA levels were quantified either with a
PhosphorImager (Molecular Dynamics, Sunnyvale, Calif.) or by
densitometry (IS-1000 Digital Imaging System; Alpha Innotech Corp., San
Leandro, Calif.), and integration activity was calculated as the
percentage of the 9.7-kb HIV-1 cDNA substrate converted into the
15.1-kb integration product. Cells infected with wild type, 604del, and
revE1 contained similar levels of HIV-1 cDNA (Fig.
2), in agreement with the previous report
that 604del and revE1 each support the wild-type level of reverse
transcription following infection (35). In repeated experiments, revE1 PICs supported 30 to 50% of the level of wild-type DNA strand transfer activity (Fig. 2, compare lane 3 to lane 1; Table
1). 604del PICs, in contrast, did not
support detectable levels of DNA strand transfer activity (Fig. 2, lane
2; Table 1). Thus, these results are consistent with the interpretation that 604del is blocked at the integration step in vivo and that the
novel U5 end in the revE1 revertant virus rescues this integration defect (35).

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 2.
In vitro DNA strand transfer activity of wild-type,
604del, and revE1 PICs. The integration reactions contained wild-type
PICs (lane 1), 604del PICs (lane 2), and revE1 PICs (lane 3). cDNA,
9.7-kb HIV-1 integration substrate; IP, 15.1-kb integration product.
|
|
To analyze the extent of 3' processing that occurred during virus
infection, cytoplasmic extract (1 ml) was deproteinized by treating it
overnight at 56°C with 50 µl of a 10-mg/ml solution of proteinase
K, 60 µl of a 10% (wt/vol) solution of sodium dodecyl sulfate (SDS),
and 12 µl of 0.5 M EDTA. Following extraction with phenol,
phenol-chloroform (1:1), and chloroform, DNA was recovered by
precipitation with ethanol. The DNA was reacted with 20 U each of
restriction enzymes HaeIII and HindIII in
buffer (50 µl) as recommended by the manufacturer (New England
Biolabs, Inc., Beverly, Mass.). Following digestion with RNase A (10 µg per ml for 30 min at 37°C), DNA was recovered by precipitation
with ethanol and resuspended in 6 µl of TE buffer (10 mM Tris-HCl
[pH 8.0], 1 mM EDTA). The sample was heated at 68°C for 30 min, 6 µl of sequencing stop buffer (95% formamide, 20 mM EDTA, 0.05%
[wt/vol] bromophenol blue, 0.05% [wt/vol] xylene cyanol) was
added, and the sample was reheated at 68°C for 30 min, followed by
boiling for 3 min. DNA (6 µl) was electrophoresed at 60 W through a
6% denaturing polyacrylamide gel until the bromophenol blue dye
reached the bottom of the gel. The DNA was transferred to Duralon-UV
Membrane (Stratagene, La Jolla, Calif.) in 44.5 mM Tris base-44.5 mM
borate-1 mM EDTA (pH 8.3) for 1 h at 12 V, 390 mA, using a Genie
Electrophoretic Blotter (Idea Scientific, Minneapolis, Minn.).
The U3 minus strand and U5 plus strand of retroviral cDNA are processed
by integrase (Fig. 3). The other two
strands, the U3 plus and U5 minus, which are not processed by
integrase, are referred to here as nonprocessed strands. The structures
of the processed and nonprocessed U3 and U5 strands were detected using strand-specific riboprobes (Fig. 3). For the nonprocessed strands, U3-
and U5-specific riboprobes were synthesized from
EcoRV-digested pMM104 and BstYI-cut pMM106
plasmid DNA (27), respectively, using T3 RNA polymerase as
recommended by the manufacturer (Promega Corp., Madison, Wis.).
Similarly, U3- and U5-specific riboprobes for detecting processed HIV-1
strands were synthesized from BamHI-cut pMM104 and
HindIII-digested pMM105 (27), respectively,
using T7 RNA polymerase. In this way, wild-type nonprocessed U3 plus and U5 minus strands were detected as 103- and 101-base fragments, respectively (Fig. 3). Whereas the U3 minus strands were detected as
103- and 101-base fragments depending on the extent of integrase 3'
processing, the wild-type U5 plus strand was detected as 105- and
103-base fragments (Fig. 3). Membranes hybridized at 68°C for 1 h in QuikHyb hybridization solution (Stratagene) containing 0.3 mg of
tRNA per ml and 2 × 106 to 5 × 106
cpm of riboprobe per ml were washed twice for 15 min at room temperature in 300 mM NaCl-30 mM sodium citrate-0.1% SDS, followed by a wash for 30 min at 60°C in 15 mM NaCl-1.5 mM sodium
citrate-0.1% SDS. Levels of 3' processing activity were detected by
autoradiography, quantified by densitometry, and expressed as the
percentage of the U3 minus strand or U5 plus strand that was converted
into the
2 cleavage product.

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 3.
Strategy for detecting 3' processing activity in
infected cell extracts. HaeIII and HindIII
cleave HIV-1 cDNA approximately 100 bp from the U3 and U5 ends,
respectively. 3' processing by integrase shortens the U3 minus strand
and U5 plus strand by 2 nucleotides (nt). Following cell lysis and
cleavage with HaeIII and HindIII, both
processed and nonprocessed strands were detected by indirect end
labeling using strand-specific riboprobes.
|
|
Similar to the results of Southern blotting presented in Fig. 2, levels
of unintegrated linear HIV-1 cDNA as detected by indirect end labeling
were identical in cells infected with wild type, 604del, and revE1
(Fig. 4). The U5 ends of wild type,
604del, and revE1 migrated during electrophoresis to positions that
were consistent with the 26- and 47-bp deletions in 604del and revE1, respectively (Fig. 4A and C). Apart from integrase-specific 3' processing of the U3 minus and U5 plus strands, all four cDNA strands
of wild type, 604del, and revE1 were intact, indicating that the cDNAs
in these PICs were not subject to cellular exonuclease activities in
vivo (Fig. 4). Integrase processed about 77 and 60% of the wild-type
U5 and U3 ends, respectively (Fig. 4A and B, lanes 1; Table 1). We were
surprised to find that integrase cleaved the U5 end of 604del with an
efficiency similar to that of wild type: about 72% of the U5 end and
about 34% of U3 604del were cleaved (Fig. 4A and B, lanes 2; Table 1).
In the case of the revE1 revertant, about 40% of U5 and 54% of U3
were processed by integrase (Fig. 4A and B, lanes 3; Table 1).

View larger version (56K):
[in this window]
[in a new window]
|
FIG. 4.
Structure of wild-type, 604del, and revE1 cDNA ends and
detection of in vivo 3' processing activity. (A) The processed U5 plus
strand. Lane 1, DNA from wild-type-infected cells; lane 2, DNA from
604del-infected cells; lane 3, DNA from revE1-infected cells. WT(+)sss,
cleavage product of wild-type plus-strand strong-stop DNA; WTun, the
unprocessed wild-type strand (105 nucleotides); WTpro, the processed
wild-type strand (103 nucleotides); 604(+)sss, cleavage product of
604del plus-strand strong-stop DNA; 604un, the unprocessed 604del
strand (79 nucleotides); 604pro, the processed 604del strand (77 nucleotides); REV(+)sss, cleavage product of revE1 plus-strand
strong-stop DNA; REVun, the unprocessed revE1 strand (60 nucleotides);
REVpro, the processed revE1 strand (58 nucleotides). (B) The processed
U3 minus strand. The samples in lanes 1 to 3 were the same as those in
panel A. un, the 103-nucleotide unprocessed minus strand; pro, the
processed 101-nucleotide product. (C) The nonprocessed U5 minus strand.
The samples in lanes 1 to 3 were the same as those in panel A. The
wild-type, 604del, and revE1 nonprocessed strands are indicated as
WTnon, 604non, and REVnon, respectively. The higher-molecular-weight
bands in lanes 1 to 3 display mobilities consistent with the
minus-strand strong-stop products of each of the viruses. (D) The
nonprocessed U3 plus strand. The samples in lanes 1 to 3 were the same
as those in panel A. non, the 103-nucleotide nonprocessed strand. For
panels A and C, the DNA levels in lanes 2 and 3 appear lower than the
levels in lanes 1 because the 604del and revE1 deletions removed U5
sequences that are present in these wild-type-derived riboprobes. The
sizes of the unprocessed, processed, and nonprocessed U5 and U3 strands
were confirmed by comparing their migration distances to those of an
M13 sequencing ladder (31).
|
|
Two activities of retroviral integrase, 3' processing and DNA strand
transfer, are required to covalently join the 3' ends of viral cDNA to
5'-phosphates at the site of integration in chromosomal DNA
(2). Numerous groups previously analyzed changes in
integrase and DNA substrates for their effects on the in vitro 3'
processing and DNA strand transfer activities of purified integrase
protein (6, 9-11, 15, 19-24, 32, 34-37). The majority of
these changes were found to similarly affect 3' processing and DNA
strand transfer (6, 9, 10, 15, 19, 21-24, 32, 34-37),
which is taken as evidence that a single active site in the integrase
protein catalyzes both enzyme activities (2). The effects of
mutations in either integrase or the DNA substrate on both 3'
processing and DNA strand transfer activities as catalyzed by the PICs
that form in infected cells, however, have not been previously
reported. In the case of HIV-1, this was in part due to the lack of a
system with which to initiate efficient tissue culture infections from molecular DNA clones. Our recent description of such a system (8) has allowed us for the first time to assess the effects of att site changes on both 3' processing and DNA strand
transfer as promoted by the integrase-containing PIC that mediates
viral integration in vivo.
Results of in vitro integration assays using purified recombinant HIV-1
integrase and synthetic oligonucleotide substrates previously suggested
that novel U5 sequences in revE1 restored an integration defect to
replication-defective 604del (35). Indeed, our results using
PICs support this contention. Consistent with the results of that
report, we found that cells infected with wild type, 604del, and revE1
contained similar levels of unintegrated HIV-1 cDNA (Fig. 2 and 4).
Whereas 604del PICs did not display detectable levels of in vitro DNA
strand transfer activity, revE1 PICs supported 30 to 50% of the level
of wild-type activity (Fig. 2 and Table 1). Since revE1 originated in
cells infected with 604del, 604del must integrate in vivo at some
frequency. We speculate that this level of DNA strand transfer activity
is below the limit of detection of our Southern blotting system. In
contrast to the results of the DNA strand transfer assays, we were
surprised to find that there were only slight differences in the
efficiencies with which the 3' ends of wild type, 604del, and revE1
were processed by integrase in vivo. The approximate 87% efficiency
with which the U5 end of 604del was processed in infected cells
compared to that in wild type (Table 1) differs significantly from the
previously reported 10% efficiency using purified integrase protein
and oligonucleotide substrate DNA (35). This result
emphasizes the importance of examining mutant viral integration
phenotypes in vivo as well as in vitro. Although the U3 end of 604del
was processed about 1.7-fold less efficiently than was the
corresponding revE1 end, this difference would not seem to account for
the rather large difference (
10-fold) in in vitro DNA strand transfer
activities supported by these PICs (Table 1). We therefore conclude
that 604del is blocked in its ability to replicate in cells at a step
that is after 3' processing but either before or at integrase-catalyzed
strand transfer of endogenous cDNA into a host cell chromosome.
It is unclear what aspect(s) of PIC biology might be defective in
604del-infected cells. One function that PICs most likely perform after
3' processing but before DNA strand transfer is transporting retroviral
cDNA from the cell cytoplasm into the nucleus (4, 17, 25,
27) (Fig. 4). Whereas simpler oncoretroviruses such as Moloney
murine leukemia virus require mitosis for their PICs to gain access to
chromosomal DNA for integration (30), lentiviruses such as
HIV-1 can be actively transported into the nuclei of nondividing cells
by an energy-dependent process (5). The C8166 cells used in
this study, however, were rapidly dividing, so 604del PICs could
readily gain access to chromosomal DNA during mitosis when the nuclear
membrane breaks down. Because the cytoplasmic extract of
604del-infected cells did not support a detectable level of in vitro
DNA strand transfer activity (Fig. 2), the integration defect appears
to manifest itself prior to nuclear localization.
To further investigate this integration defect, wild-type, 604del and
revE1 PICs purified by Nycodenz gradient centrifugation were analyzed
by MM-PCR footprinting as previously described (8). The
purified PICs were divided into two fractions, and one of these
fractions was deproteinized to serve as naked DNA control during DNA
footprinting (Fig. 1). MM-PCR uses Mu transpososomes as the DNA
footprinting reagent (8, 39). Proteins important for
integration protect the ends of retroviral cDNA from attack by Mu,
revealing footprints in the native protein-DNA samples that are absent
from deproteinized controls (8, 39). In addition to these
approximately 200-bp footprinted regions at the U3 and U5 ends of
retroviral cDNA, hot spots of Mu insertion occur near the very ends of
the viruses (1, 8, 39). This native protein-cDNA complex in
retroviral PICs, typified by these end-specific transpositional footprints and enhanced regions, is referred to as the retroviral intasome (8, 39). Numerous analyses of retroviruses by
MM-PCR footprinting, including integrase and att site mutant
PICs (8, 39, 40), functional reconstitution of wild-type
PICs using host cell extracts or purified proteins after treatment with
high concentrations of salt (7, 39, 40), and functional
interference footprinting (39), have established a central
role for the intasome in the integration of endogenous retroviral cDNA.
Oligonucleotides AE347 (1) and AE459 (8) were
used in second PCR rounds to analyze the U3 and U5 ends, respectively, by MM-PCR. As previously shown, the frequency and distribution of Mu
transposition into deproteinized HIV-1 cDNA were nearly identical to
those for a naked plasmid DNA control (Fig. 5A and B, compare lanes 2 to lanes 1). Also as
expected, the U3 and U5 ends of native wild-type PICs displayed the
end-specific transpositional footprinted and enhanced regions that
define the retroviral intasome (Fig. 5A and B, compare lanes 3 to lanes
2). Native revE1 PICs also displayed the intasome structure, although
in this case the transpositional enhancements were less pronounced than
those for wild-type U3 and U5 (Fig. 5A and B, compare lanes 7 to lanes
3). This lower level of end-specific Mu transposition may reflect the
lower level of DNA strand transfer activity supported by revE1 PICs
than by wild type (Fig. 2 and Table 1) (7). In contrast to
the results obtained with revE1, native 604del PICs displayed only a
minimal protein-DNA structure. In repeated experiments, regions of
protein footprints were not detected, and only slight transpositional
enhancements were observed (Fig. 5A and B, compare lanes 5 to lanes 4).
It therefore seems that the majority of the protein factors responsible
for the wild-type HIV-1 intasome as detected by MM-PCR footprinting
either were absent from 604del PICs following Nycodenz gradient
centrifugation or were loosely bound such that in vitro transposition
readily displaced them from the cDNA. To investigate whether this
protein-DNA structure defect might be due to the loss of the majority
of PIC-associated proteins that occurred during sample preparation
and/or purification, gradient-purified PICs were analyzed for integrase
content by Western blotting essentially as previously described
(8). The results of this experiment revealed that wild-type,
604del, and revE1 PICs contained similar levels of integrase protein
(Fig. 6). Thus, the vast majority of
HIV-1 integrase remained associated with 604del cDNA during gradient
purification.

View larger version (77K):
[in this window]
[in a new window]
|
FIG. 5.
MM-PCR footprints of wild-type, 604del, and revE1 PICs.
(A) The U3 end of HIV-1. In lane 1, naked plasmid DNA was used as the
target for Mu transposition. Lane 2, deproteinized wild-type cDNA; lane
3, native wild-type PICs; lane 4, deproteinized 604del cDNA; lane 5, native 604del PICs; lane 6, deproteinized revE1 cDNA; lane 7, revE1
PICs. E, region of transpositional enhancements; F, footprinted
regions. Although the deproteinized 604del cDNA in lane 4 did not
amplify well, results of other experiments showed that this pattern of
Mu transposition was indistinguishable from the wild-type and revE1
deproteinized cDNA patterns in lanes 2 and 6, respectively. (B) The U5
end. The samples in lanes 1 to 7 were the same as those in panel A. WT-E, the wild-type region of transpositional enhancements; WT-F, the
wild-type footprinted region; 604-E, 604del region of weak
transpositional enhancements; rev-E, the revE1 region of
transpositional enhancements; rev-F, the revE1 footprinted region. The
U5 ends of 604del and revE1 were shorter in panel B due to the 26- and
47-bp deletions, respectively. Due to the polarity of Mu transposition,
only the very ends of the nonprocessed U3 and U5 strands can be
analyzed by MM-PCR (8, 39).
|
|

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 6.
Integrase protein content of gradient-purified
wild-type, 604del, and revE1 PICs. Lane 1, 50 ng of recombinant HIV-1
integrase; lane 2, 25 ng of recombinant integrase; lane 3, gradient-purified wild-type PICs; lane 4, 604del PICs; lane 5, revE1
PICs. IN, integrase.
|
|
Although the U3 end of 604del has the wild-type sequence, it, like the
mutant U5 end, showed little evidence of protein binding (Fig. 5).
Similarly, it was previously shown that a replication-defective Moloney
murine leukemia virus U3 att site mutant lacked detectable protein binding at both U3 and U5, even though in this case U5 was wild
type in sequence (40). In contrast to the results reported here, that single-end att site mutation blocked 3'
processing of both viral ends in vivo (28). We therefore
conclude that a mutation in just one end of the retroviral
att site can influence functional protein-DNA interactions
at both ends regardless of successful 3' processing by integrase. The
finding that the novel U5 end in revE1 partially restored both PIC
activity (Fig. 2) and intasome structure (Fig. 5) further highlights
the functional relevance of the retroviral intasome.
Whereas results of Southern blotting showed that cytoplasmic extracts
of wild-type-, 604del-, and revE1-infected cells contained similar
levels of unintegrated linear cDNA (Fig. 2), results of indirect end
labeling showed that the ends of these cDNAs were intact (Fig. 4). Yet,
results of MM-PCR footprinting suggested that protein factors that bind
to the ends of HIV-1 cDNA and are important for in vitro integration
activity were for the most part absent from gradient-purified 604del
PICs (Fig. 5). Because of this, we next investigated whether the 604del
replication defect might be due in part to degradation of this cDNA
after it enters the cell nucleus. In addition to the linear cDNA
integration substrate, two different circular forms of retroviral DNA,
containing either one or two copies of the viral long terminal repeat
(LTR), are found in the nuclei of infected cells (reviewed in reference
2). The two-LTR circle is readily detected by PCR
because the unique LTR-LTR junction is absent from potentially
contaminating plasmid DNA. Cells infected with integration-specific
retroviral mutants tend to contain higher levels of the two-LTR circle
than do wild-type-infected controls (reviewed in reference
14). To investigate the nuclear viability of
unintegrated 604del DNA, CEM-12D7 cells infected with wild type,
604del, and integration-defective HIV-1 integrase mutants containing
either the substitution of Lys for Gln-62 (Q62K) or Asn for Asp-116
(D116N) (8) were lysed and analyzed for two-LTR circle
content using nested PCR essentially as previously described
(1). One exception here is that U5-specific primers AE322
and AE609 (1) were used in the first and second PCR rounds, respectively, because the previously described second-round U5 primer
coincided with the 604del deletion. Because of this deletion, 604del
two-LTR circles displayed an electrophoretic mobility that was faster
than that of wild type and integrase mutants Q62K and D116N (Fig.
7, compare lane 2 to lanes 1, 3, and 4).
Importantly, cells infected with 604del contained two-LTR circles at a
level that was similar to the levels detected for Q62K and D116N (Fig. 7). Thus, nucleus-associated 604del cDNA is apparently as stable as
wild type and these integration-defective HIV-1 integrase mutants.

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 7.
Two-LTR circle content of cells infected with wild type,
604del, and integrase mutants Q62K and D116N. Lane 1, lysate from cells
infected with wild type; lane 2, lysate from 604del-infected cells;
lane 3, lysate from Q62K-infected cells; lane 4, lysate from
D116N-infected cells; lane 5, lysate from mock-infected cells. 222 and
196 indicate the sizes of PCR products for wild type and 604del,
respectively, in base pairs.
|
|
Based on our observations that integrase processed the 3' ends of
604del in vivo with an efficiency similar to that for revE1 and wild
type (Fig. 4 and Table 1) and that 604del PICs were selectively
defective for in vitro DNA strand activity (Fig. 2 and Table 1) and
intasome structure (Fig. 5) despite containing the majority of their
integrase protein (Fig. 6), we propose that protein factors important
for DNA strand transfer activity either do not properly associate with
604del cDNA or dissociate from this cDNA more readily than they do from
either wild type or revE1 following in vivo 3' processing. We conclude
that this is an integration-specific defect because it did not render
604del cDNA susceptible to nuclease attack by cellular enzymes (Fig. 2,
4, and 7). Although the mechanistic basis for this defect is unclear,
it depends on the novel U5 sequence in 604del.
Results of in vitro integration assays using purified HIV-1 integrase
protein and oligonucleotide substrate DNA revealed that the
nonprocessed 5' AC overhang produced by 3' processing contributes to
the stability of the functional integrase-viral DNA complex (13). Since this terminus is identical in wild type, 604del, and revE1, we speculate that subterminal U5 sequences might also affect
the stability of functional integrase-viral DNA interactions after 3'
processing in vivo. To the best of our knowledge, 604del is the first
example of a replication-defective mutant that is blocked in its
ability to grow in cells at the integration step despite processing the
3' ends of retroviral cDNA at nearly normal levels. Based on this novel
finding, we speculate that it may be possible to isolate inhibitors of
HIV-1 integration that block virus replication after the 3' processing
step of retroviral integration.
 |
ACKNOWLEDGMENTS |
We thank M. Miller for plasmid DNAs and valued advice and M. Mizuuchi for purified Mu A protein.
This work was supported by NIH grant AI39394, by the G. Harold and
Lelia Y. Mathers Foundation, and by the Friends of Dana-Farber Cancer Institute.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Cancer Immunology and AIDS, Dana-Farber Cancer Institute, 44 Binney
St., Boston, MA 02115. Phone: (617) 632-4361. Fax: (617) 632-3113. E-mail: alan_engelman{at}dfci.harvard.edu.
 |
REFERENCES |
| 1.
|
Brown, H. E. V.,
H. Chen, and A. Engelman.
1999.
Structure-based mutagenesis of the human immunodeficiency virus DNA attachment site: effects on integration and cDNA synthesis.
J. Virol.
73:9011-9020[Abstract/Free Full Text].
|
| 2.
|
Brown, P. O.
1997.
Integration, p. 161-203.
In
J. M. Coffin, S. H. Hughes, and H. E. Varmus (ed.), Retroviruses. Cold Spring Harbor Laboratory Press, Plainview, N.Y.
|
| 3.
|
Brown, P. O.,
B. Bowerman,
H. E. Varmus, and J. M. Bishop.
1987.
Correct integration of retroviral DNA in vitro.
Cell
49:347-356[CrossRef][Medline].
|
| 4.
|
Brown, P. O.,
B. Bowerman,
H. E. Varmus, and J. M. Bishop.
1989.
Retroviral integration: structure of the initial covalent product and its precursor, and a role for the viral IN protein.
Proc. Natl. Acad. Sci. USA
86:2525-2529[Abstract/Free Full Text].
|
| 5.
|
Bukrinsky, M. I.,
N. Sharova,
M. P. Dempsey,
T. L. Stanwick,
A. G. Bukrinskaya,
S. Haggerty, and M. Stevenson.
1992.
Active nuclear import of human immunodeficiency virus preintegration complexes.
Proc. Natl. Acad. Sci. USA
89:6580-6584[Abstract/Free Full Text].
|
| 6.
|
Bushman, F. D., and R. Craigie.
1991.
Activities of human immunodeficiency virus (HIV) integration protein in vitro: specific cleavage and integration of HIV DNA.
Proc. Natl. Acad. Sci. USA
88:1339-1343[Abstract/Free Full Text].
|
| 7.
|
Chen, H., and A. Engelman.
1998.
The barrier-to-autointegration protein is a host factor for HIV type 1 integration.
Proc. Natl. Acad. Sci. USA
95:15270-15274[Abstract/Free Full Text].
|
| 8.
|
Chen, H.,
S.-Q. Wei, and A. Engelman.
1999.
Multiple integrase functions are required to form the native structure of the human immunodeficiency virus type 1 intasome.
J. Biol. Chem.
274:17358-17364[Abstract/Free Full Text].
|
| 9.
|
Craigie, R.,
T. Fujiwara, and F. Bushman.
1990.
The IN protein of Moloney murine leukemia virus processes the viral DNA ends and accomplishes their integration in vitro.
Cell
62:829-837[CrossRef][Medline].
|
| 10.
|
Drelich, M.,
R. Wilhelm, and J. Mous.
1992.
Identification of amino acid residues critical for endonuclease and integration activities of HIV-1 IN protein in vitro.
Virology
188:459-468[CrossRef][Medline].
|
| 11.
|
Du, Z.,
P. O. Ilyinskii,
K. Lally,
R. C. Desrosiers, and A. Engelman.
1997.
A mutation in integrase can compensate for mutations in the simian immunodeficiency virus att site.
J. Virol.
71:8124-8132[Abstract].
|
| 12.
|
Ellison, V.,
H. Abrams,
T. Roe,
J. Lifson, and P. O. Brown.
1990.
Human immunodeficiency virus integration in a cell-free system.
J. Virol.
64:2711-2715[Abstract/Free Full Text].
|
| 13.
|
Ellison, V., and P. O. Brown.
1994.
A stable complex between integrase and DNA ends mediates human immunodeficiency virus integration in vitro.
Proc. Natl. Acad. Sci. USA
91:7316-7320[Abstract/Free Full Text].
|
| 14.
|
Engelman, A.
1999.
In vivo analysis of retroviral integrase structure and function.
Adv. Virus Res.
52:411-426[Medline].
|
| 15.
|
Engelman, A., and R. Craigie.
1992.
Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro.
J. Virol.
66:6361-6369[Abstract/Free Full Text].
|
| 16.
|
Farnet, C. M., and W. A. Haseltine.
1990.
Integration of human immunodeficiency virus type 1 DNA in vitro.
Proc. Natl. Acad. Sci. USA
87:4164-4168[Abstract/Free Full Text].
|
| 17.
|
Fujiwara, T., and K. Mizuuchi.
1988.
Retroviral DNA integration: structure of an integration intermediate.
Cell
54:497-504[CrossRef][Medline].
|
| 18.
|
Katz, R. A.,
G. Merkel,
J. Kulkosky,
J. Leis, and A. M. Skalka.
1990.
The avian retroviral IN protein is both necessary and sufficient for integrative recombination in vitro.
Cell
63:87-95[CrossRef][Medline].
|
| 19.
|
Katz, R. A.,
J. P. G. Mack,
G. Merkel,
J. Kulkosky,
Z. Ge,
J. Leis, and A. M. Skalka.
1992.
Requirement for a conserved serine in both processing and joining activities of retroviral integrase.
Proc. Natl. Acad. Sci. USA
89:6741-6745[Abstract/Free Full Text].
|
| 20.
|
Katzman, M.,
R. A. Katz,
A. M. Skalka, and J. Leis.
1989.
The avian retroviral integration protein cleaves the terminal sequences of linear viral DNA at the in vivo sites of integration.
J. Virol.
63:5319-5327[Abstract/Free Full Text].
|
| 21.
|
Kulkosky, J.,
K. S. Jones,
R. A. Katz,
J. P. G. Mack, and A. M. Skalka.
1992.
Residues critical for retroviral integrative recombination in a region that is highly conserved among retroviral/retrotransposon integrases and bacterial insertion sequence transposases.
Mol. Cell. Biol.
12:2331-2338[Abstract/Free Full Text].
|
| 22.
|
Lafemina, R. L.,
P. L. Callahan, and M. G. Cordingley.
1991.
Substrate specificity of recombinant human immunodeficiency virus integrase protein.
J. Virol.
65:5624-5630[Abstract/Free Full Text].
|
| 23.
|
Leavitt, A. D.,
R. B. Rose, and H. E. Varmus.
1992.
Both substrate and target oligonucleotide sequences affect in vitro integration mediated by the human immunodeficiency virus type 1 integrase protein produced in Saccharomyces cerevisiae.
J. Virol.
66:2359-2368[Abstract/Free Full Text].
|
| 24.
|
Leavitt, A. D.,
L. Shiue, and H. E. Varmus.
1993.
Site-directed mutagenesis of HIV-1 integrase demonstrates differential effects on integrase function in vitro.
J. Biol. Chem.
268:2113-2119[Abstract/Free Full Text].
|
| 25.
|
Lee, Y. M. H., and J. M. Coffin.
1991.
Relationship of avian retrovirus DNA synthesis to integration in vitro.
Mol. Cell. Biol.
11:1419-1430[Abstract/Free Full Text].
|
| 26.
|
Masuda, T.,
V. Planelles,
P. Krogstad, and I. S. Y. Chen.
1995.
Genetic analysis of human immunodeficiency virus type 1 integrase and U3 att site: unusual phenotype of mutants in the zinc finger-like domain.
J. Virol.
69:6687-6696[Abstract].
|
| 27.
|
Miller, M. D.,
C. M. Farnet, and F. D. Bushman.
1997.
Human immunodeficiency type 1 preintegration complexes: studies of organization and function.
J. Virol.
71:5382-5390[Abstract].
|
| 28.
|
Murphy, J. E., and S. P. Goff.
1992.
A mutation at one end of Moloney murine leukemia virus DNA blocks cleavage at both ends by the viral integrase in vivo.
J. Virol.
66:5092-5095[Abstract/Free Full Text].
|
| 29.
|
Pauza, C. D.
1990.
Two bases are deleted from the termini of HIV-1 linear DNA during integrative recombination.
Virology
179:886-889[CrossRef][Medline].
|
| 30.
|
Roe, T.,
T. C. Reynolds,
G. Yu, and P. O. Brown.
1993.
Integration of murine leukemia virus depends on mitosis.
EMBO J.
12:2099-2108[Medline].
|
| 31.
|
Roth, M. J.,
P. L. Schwartzberg, and S. P. Goff.
1989.
Structure of the termini of DNA intermediates in the integration of retroviral DNA: dependence on IN function and terminal DNA sequence.
Cell
58:47-54[CrossRef][Medline].
|
| 32.
|
Sherman, P. A.,
M. L. Dickson, and J. A. Fyfe.
1992.
Human immunodeficiency virus type 1 integration protein: DNA sequence requirements for cleavage and joining reaction.
J. Virol.
66:3593-3601[Abstract/Free Full Text].
|
| 33.
|
Sherman, P. A., and J. A. Fyfe.
1990.
Human immunodeficiency virus integration protein expressed in Escherichia coli possesses selective DNA cleaving activity.
Proc. Natl. Acad. Sci. USA
87:5119-5123[Abstract/Free Full Text].
|
| 34.
|
van Gent, D. C.,
A. A. M. Oude Groeneger, and R. H. A. Plasterk.
1992.
Mutational analysis of the integrase protein of human immunodeficiency virus type 2.
Proc. Natl. Acad. Sci. USA
89:9598-9602[Abstract/Free Full Text].
|
| 35.
|
Vicenzi, E.,
D. S. Dimitrov,
A. Engelman,
T.-H. Migone,
D. A. F. Purcell,
J. Leonard,
G. Englund, and M. A. Martin.
1994.
An integration-defective U5 deletion mutant of human immunodeficiency virus type 1 reverts by eliminating additional long terminal repeat sequences.
J. Virol.
68:7879-7890[Abstract/Free Full Text].
|
| 36.
|
Vincent, K. A.,
V. Ellison,
S. A. Chow, and P. O. Brown.
1993.
Characterization of human immunodeficiency virus type 1 integrase expressed in Escherichia coli and analysis of variants with amino-terminal mutations.
J. Virol.
67:425-437[Abstract/Free Full Text].
|
| 37.
|
Vink, C.,
D. C. van Gent,
Y. Elgersma, and R. H. A. Plasterk.
1991.
Human immunodeficiency virus integrase protein requires a subterminal position of its viral DNA recognition sequence for efficient cleavage.
J. Virol.
65:4636-4644[Abstract/Free Full Text].
|
| 38.
|
Vora, A. C.,
M. L. Fitzgerald, and D. P. Grandgenett.
1990.
Removal of 3'-OH-terminal nucleotides from blunt-ended long terminal repeat termini by the avian retrovirus integration protein.
J. Virol.
64:5656-5659[Abstract/Free Full Text].
|
| 39.
|
Wei, S.-Q.,
K. Mizuuchi, and R. Craigie.
1997.
A large nucleoprotein assembly at the ends of the viral DNA mediates retroviral DNA integration.
EMBO J.
16:7511-7520[CrossRef][Medline].
|
| 40.
|
Wei, S.-Q.,
K. Mizuuchi, and R. Craigie.
1998.
Footprints on the viral DNA ends in Moloney murine leukemia virus preintegration complexes reflect a specific association with integrase.
Proc. Natl. Acad. Sci. USA
95:10535-10540[Abstract/Free Full Text].
|
Journal of Virology, September 2000, p. 8188-8193, Vol. 74, No. 17
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Pandey, K. K., Bera, S., Zahm, J., Vora, A., Stillmock, K., Hazuda, D., Grandgenett, D. P.
(2007). Inhibition of Human Immunodeficiency Virus Type 1 Concerted Integration by Strand Transfer Inhibitors Which Recognize a Transient Structural Intermediate. J. Virol.
81: 12189-12199
[Abstract]
[Full Text]
-
Philippe, S., Sarkis, C., Barkats, M., Mammeri, H., Ladroue, C., Petit, C., Mallet, J., Serguera, C.
(2006). Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo. Proc. Natl. Acad. Sci. USA
103: 17684-17689
[Abstract]
[Full Text]
-
Lu, R., Limon, A., Ghory, H. Z., Engelman, A.
(2005). Genetic Analyses of DNA-Binding Mutants in the Catalytic Core Domain of Human Immunodeficiency Virus Type 1 Integrase. J. Virol.
79: 2493-2505
[Abstract]
[Full Text]
-
Vora, A., Bera, S., Grandgenett, D.
(2004). Structural Organization of Avian Retrovirus Integrase in Assembled Intasomes Mediating Full-site Integration. J. Biol. Chem.
279: 18670-18678
[Abstract]
[Full Text]
-
Limon, A., Devroe, E., Lu, R., Ghory, H. Z., Silver, P. A., Engelman, A.
(2002). Nuclear Localization of Human Immunodeficiency Virus Type 1 Preintegration Complexes (PICs): V165A and R166A Are Pleiotropic Integrase Mutants Primarily Defective for Integration, Not PIC Nuclear Import. J. Virol.
76: 10598-10607
[Abstract]
[Full Text]
-
Chen, H., Engelman, A.
(2001). Asymmetric Processing of Human Immunodeficiency Virus Type 1 cDNA In Vivo: Implications for Functional End Coupling during the Chemical Steps of DNA Transposition. Mol. Cell. Biol.
21: 6758-6767
[Abstract]
[Full Text]